We observed recovery of 97% of sgRNAs from tumor samples (Supplemental Data 2) and strong enrichment of sgRNAs targeting the Pdcd1 gene (FDR-adjusted P < 1 × 10–16). This evidence concerns the gene PDCD1 and neoplasm.